Jazz Pharma To Highlight Both Clinical And Preclinical Research Evaluating Modeyso And New Preclinical Data Featuring JZP3507 In CNS Tumors, At 2025 SNO Annual Meeting

Author: Benzinga Newsdesk | November 11, 2025 07:48am

Data highlight continued progress in Jazz's brain tumor research and demonstrate the company's commitment to advancing treatment options for patients with rare and aggressive brain tumors

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the company will present five abstracts at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting taking place November 19-23 in Honolulu, Hawaii. The presentations will feature both clinical and preclinical research evaluating Modeyso™ (dordaviprone), as well as new preclinical data featuring JZP3507 (formerly ONC206) in central nervous system (CNS) tumors, reflecting Jazz's growing impact and innovation in neuro-oncology.

Key presentations include:

• New translational research characterizing potential molecular pathways associated with sensitivity to dordaviprone and exploring how targeted combination strategies may help to enhance response.
• Preclinical data evaluating how dordaviprone may influence the tumor immune environment to inform future research on rational immunotherapy combinations.

Posted In: JAZZ